L. Schwartzberg

发表

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

Amy M. Sitapati, Amy Sitapati, Andres Forero, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.

M. Arbushites, S. Stein, K. Blackwell, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Breast cancer version 3.2014.

B. Ljung, C. Hudis, W. Gradishar, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

H. Rugo, M. Aapro, I. Bondarenko, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy

G. Demetri, A. Saven, J. Rigas, 2001, British Journal of Cancer.

Invasive breast cancer version 1.2016

C. Hudis, W. Gradishar, Rashmi Kumar, 2016 .

NCCN Guidelines Insights Breast Cancer, Version 1.2016.

C. Hudis, W. Gradishar, Rashmi Kumar, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

A. Tulpule, B. Cheson, Michael E. Williams, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Defining a therapeutic dose of peripheral blood stem cells.

L. To, L. Schwartzberg, J. Bender, 1992, Journal of hematotherapy.

NCCN Guidelines Insights: Breast Cancer, Version 1.2017.

Amy M. Sitapati, W. Gradishar, Rashmi Kumar, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Breast cancer version 2.2015: Clinical practice guidelines in oncology

Benjamin O. Anderson, Matthew Philip Goetz, Lee S. Schwartzberg, 2015 .

A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).

K Miller, E. Winer, R. Carlson, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma

J. Hecht, G. Fasola, J. Canon, 2017, International Journal of Colorectal Disease.

Health and Quality of Life Outcomes

C. Chiou, T. Mcgarrity, L. Peiffer, 2006 .

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.

B. Taylor, S. Loi, S. Chandarlapaty, 2019, Cancer discovery.

The relation of trouble sleeping, depressed mood, pain, and fatigue in patients with cancer.

E. Stepanski, J. Ong, L. Schwartzberg, 2009, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

High-dose chemotherapy and autologous stem cell transplantation for breast cancer.

L. Schwartzberg, R. Birch, C. Weaver, 1995, Cancer treatment and research.

Acute chest pain syndrome during bleomycin infusions

M. Kris, G. Bosl, D. White, 1987, Cancer.

J. Hainsworth, F. Greco, L. Schwartzberg, 1997, Bone Marrow Transplantation.

A phase I–II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma

J. Hainsworth, F. Greco, L. Schwartzberg, 1997, Bone Marrow Transplantation.

Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer.

D. Mintzer, F. Arena, M. Walker, 2012, Clinical breast cancer.

Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study

P. Fasching, P. Goss, G. Curigliano, 2017, Breast Cancer Research and Treatment.

The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting

A. Molassiotis, M. Aapro, G. Dranitsaris, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy

R. Gralla, E. Roeland, R. Navari, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.

Michael C. Mosier, Robert E. Smith, N. Gabrail, 2016, Future oncology.

Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content

L. Schwartzberg, P. Unger, C. Buckner, 1997, Bone Marrow Transplantation.

Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer.

J. Hainsworth, F. Greco, L. Schwartzberg, 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer

C. Isaacs, S. Swain, A. Tan, 2020, Frontiers in Oncology.

Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.

John D. Roberts, C. Bloomfield, N. Christakis, 2005, Journal of the National Cancer Institute.

Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 vs 4 g/m2 of CY

L. Schwartzberg, C. Buckner, C. Weaver, 1999, Bone Marrow Transplantation.

High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin’s lymphoma: results of outpatient treatment in community cancer centers

J. Hainsworth, F. Greco, L. Schwartzberg, 1997, Bone Marrow Transplantation.

Breast Cancer, Version 3.2013

B. Ljung, D. Mankoff, S. Edge, 2013 .

Toxicity and Response of Pemetrexed Plus Carboplatin or Cisplatin with Concurrent Chest Radiation Therapy for Patients with Locally Advanced Non-small Cell Lung Cancer: A Phase I Trial

C. Obasaju, R. Govindan, H. Choy, 2010 .

Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC).

J. Baselga, O. Petrenciuc, M. Shan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin’s lymphoma

L. Schwartzberg, C. Buckner, C. Weaver, 1998, Bone Marrow Transplantation.